Resources & Guides
Educational content about GLP-1 medications, pharmacokinetics, and optimizing your treatment journey.
GLP-1 Medication Hubs
Comprehensive guides for each GLP-1 medication—dosing protocols, clinical trial data, microdosing strategies, and our free calculators.
Semaglutide Guide
Ozempic & Wegovy: GLP-1 receptor agonist. ~15% weight loss, 7-day half-life. FDA-approved for diabetes and weight management.
Tirzepatide Guide
Mounjaro & Zepbound: Dual GLP-1/GIP agonist. ~21% weight loss, 5-day half-life. The first dual-agonist approved by FDA.
Retatrutide Guide
Triple GLP-1/GIP/Glucagon agonist. ~24% weight loss in trials, 6-day half-life. Expected FDA approval 2027.
Educational Content
Is Retatrutide FDA Approved? Status, Trials & Timeline (2026)
articleRetatrutide is not FDA-approved. It's currently in Phase 3 clinical trials (TRIUMPH program) with expected approval in 2027. Here's everything you need to know about its regulatory status, trial progress, and how to access it today.
Is Tirzepatide FDA Approved? Mounjaro & Zepbound Status (2026)
articleTirzepatide is FDA-approved under two brand names: Mounjaro for type 2 diabetes and Zepbound for chronic weight management and obstructive sleep apnea. Compounded tirzepatide is a different story. Here is the full approval timeline, brand-by-brand indications, eligibility, and the compounded vs brand distinction.
Where to Get Retatrutide in 2026: Availability by Source
articleRetatrutide is not commercially available. It is in Phase 3 trials with expected FDA approval in 2027-2028. Current access: clinical trials (free), compounded pharmacies ($200-500/mo), or research peptides ($150-500/mo). Here is everything you need to know about retatrutide availability worldwide.
Ozempic vs Wegovy 2026: Cost, Dosing, Weight Loss Compared
comparisonBoth Ozempic and Wegovy contain semaglutide, but Ozempic is FDA-approved for type 2 diabetes (max 1.0 mg) while Wegovy targets obesity (2.4 mg recommended maintenance, 7.2 mg maximum). Explore the differences.